Publication Date: 2017-08-21
Practice Area: Securities Litigation
Industry: Biotechnology | Investments and Investment Advisory
Date Filed: 2017-08-18
Court: 9th Cir.
Judge: Ricardo S. Martinez, Chief Judge, Presiding Before: Ronald M. Gould and Richard A. Paez, Circuit Judges, and Ivan L.R. Lemelle,*District Judge.
Attorneys: For plaintiff: Marc Ian Gross (argued), Jeremy Lieberman, and Michael J. Wernke, Pomerantz LLP, New York, New York; Jeffrey C. Block, Whitney E. Street, and Mark A. Delaney, Block & Leviton LLP, Boston, Massachusetts; Dan Drachler, Zwerling Schachter & Zwerling LLP, Seattle, Washington; for Plaintiffs-Appellants.
for defendant: Gregory L. Watts (argued), and Barry M. Kaplan, Wilson Sonsini Goodrich & Rosati, Seattle, Washington; Cheryl W. Foung, Wilson Sonsini Goodrich & Rosati, Palo Alto, California; for Defendants-Appellees.
Case Number: No. 14-35933
Securities fraud class action adequately alleged falsity and materiality of claims that company's product was FDA-approved (Gould, J.)